Roche Holding stock
Price history
+42.06% over the period1 year: from CHF 287.20 (November 17, 2025) to CHF 408.00 (November 17, 2026), +42.06%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | CHF 408.00 |
| October 30, 2026 | CHF 403.40 |
| September 30, 2026 | CHF 349.10 |
| August 31, 2026 | CHF 352.80 |
| July 31, 2026 | CHF 353.60 |
| June 30, 2026 | CHF 332.80 |
| May 29, 2026 | CHF 329.30 |
| April 30, 2026 | CHF 318.40 |
| March 31, 2026 | CHF 314.70 |
| February 27, 2026 | CHF 367.00 |
| January 30, 2026 | CHF 350.70 |
| December 30, 2025 | CHF 328.20 |
| November 28, 2025 | CHF 307.40 |
| November 17, 2025 | CHF 287.20 |
At a glance
The company
Pharmaceutical and diagnostics company offering medicines for multiple therapeutic areas and in vitro tests for disease diagnosis
Latest results
Quarter to September 30, 2026
Next event
TickerLandia's take on Roche Holding
- Pricier than usual relative to earnings: P/E on the latest fiscal year 25 vs a median of 20 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 27 vs 21 (+24%) in a group of 10.
- Strong point: Market momentum (81/100 in its group). Weak point: Growth (19/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−0.81% from the 52-week high
Analysts · 22 analysts
Average targetCHF 396.41−2.41% vs. price
Buy 11 · Hold 10 · Sell 1 · Buy
TickerLandia Fingerprint: Roche Holding
Compared with similar companies: very low growth and very strong momentum.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh70
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 14.6 70 P/E (trailing 12 months) 26.6 59 Forward P/E 18.5 73 Price/book 9.94 81 Price/sales 5.16 66 Profitabilityhigh71
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 33.1% 62 Gross margin 74.2% 58 Net margin 19.6% 74 ROE 38.1% 77 ROA 13.5% 82 Earnings stabilityhigh70
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.3% 86 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthvery low19
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −1.26% 14 Revenue growth (year over year) −1.20% 2 Earnings growth (year over year) −7.70% 40 Financial strengthaverage43
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.12 50 Interest coverage 17.7 50 Current ratio 1.23 30 Debt/equitycounts in reverse: lower means more financial strength 0.91 44 Dividendhigh60
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 32 years 68 Payout ratio 63.9% 56 Dividend yield 2.4% 56 Market momentumvery strong81
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +8.87% 77 Relative strength (6 months) +10.02% 76 1-year return +43.06% 84 Distance from 200-day average +18.04% 87 Riskaverage48
How much the price swings.
Metric Value Position in group Volatility (60 days) 22.0% 29 Beta (1 year) 1.16 82 Maximum drawdown (12 months) 19.5% 32
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Roche Holding is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Roche Holding's P/E today is 25.4, above the median of its last 10 fiscal years (20.3; between 17.1 and 24.8 from 2016 to 2025). Roche Holding's P/E (trailing 12 months): 26.7, +24% against the median of a group of 10 similar companies (21.5).
Compared with 10 similar companies
| Metric | Roche Holding | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 26.7 | High | |
| Forward P/E | 18.5 | High | |
| Operating margin | 33.1% | Middle | |
| ROE | 38.1% | High | |
| Debt/equity | 0.91 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Roche Holding. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
CHF 31.45B
Latest quarter · Q2 2026
Net income
CHF 6.87B
Latest quarter · Q2 2026
Quarterly net margin
21.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- CHF 325.56B
- P/E
- 26.7
- EPS
- CHF 15.33
- Volume
- 131.29K
- Daily trading
- €453.78M
- Dividend yield
- 2.41%
- Last ex-dividend on March 12, 2026
How Roche Holding is changing
All resultsRevenue grew 1.0% a year on average over the last 5 years
Operating margin rose from 31.3% to 33.1%
Profits turn into cash: free cash flow equal to 135% of net income
Returns
Roche Holding returns with dividends
CHF 1,000 invested in Roche Holding 5 years ago, on November 17, 2021, would be worth CHF 1,297 today with dividends reinvested: +29.70% in total, +5.34% per year. On price alone it would be CHF 1,100 (+10.03%).
| Period | Roche Holding | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | +7.34% | +4.53% | CHF 1,073 |
| 6 months | +25.84% | +13.61% | CHF 1,258 |
| Year to date | +24.31% | +13.20% | CHF 1,243 |
| 1 year | +46.44% | +19.22% | CHF 1,464 |
| 3 years | +90.39% | +39.88% | CHF 1,904 |
| 5 years | +29.70% | +19.20% | CHF 1,297 |
| 10 years | +142.59% | +88.57% | CHF 2,426 |
Over the last 6 months it has done better than 39% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Roche Holding: technical analysis
Roche Holding is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 0.8% below its all-time closing high (CHF 409.30, November 16, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 65
- Between 30 and 70
- vs 200-session average
- +17.05%
Support and resistance
Price areas where Roche Holding has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceCHF 406.20
- SupportCHF 375.10−7.66%3 touches, last on August 26, 2026
- SupportCHF 368.73−9.22%3 touches, last on September 23, 2026
- SupportCHF 348.75−14.14%2 touches, last on February 11, 2026
Volatility and risk
Over the last year it has moved roughly in line with the SMI.
- Beta (1 year) vs SMI
- 1.16
- Volatility (60 sessions, annualised)
- 22.0%
- Largest fall in the last year
- −19.55%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Roche Holding: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Roche Holding has been November: +2.47% on average, positive in 27 years out of 36. The weakest has been August: −0.73% on average, positive in 17 years out of 37.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.56% | +0.45% | 23 of 36 |
| February | +0.17% | +0.11% | 19 of 37 |
| March | −0.49% | −0.25% | 16 of 37 |
| April | +0.82% | +0.04% | 19 of 37 |
| May | +2.29% | +2.44% | 24 of 37 |
| June | −0.20% | −1.31% | 16 of 37 |
| July | +1.72% | +0.64% | 22 of 37 |
| August | −0.73% | −0.12% | 17 of 37 |
| September | −0.33% | −0.17% | 17 of 37 |
| October | +1.79% | +2.19% | 24 of 37 |
| November | +2.47% | +2.30% | 27 of 36 |
| December | +1.48% | +0.90% | 21 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Roche Holding and its competitors
Founded in 1896 and based in Basel, Switzerland, the group develops prescription medicines and runs a diagnostics business, selling its products across Europe, North and Latin America, Asia, Africa and Australia. Its drug portfolio covers oncology, immunology, neurology, ophthalmology and transplant care, while its laboratory arm offers in vitro tests for conditions such as cancer, diabetes and hepatitis, together with diagnostic instruments and digital health tools. The company also collaborates with Excalipoint Therapeutics to evaluate EXP011 in solid tumours that express DLL3.
- Headquarters
- Basel, Switzerland
- Employees
- 103,249
- Founded
- 1896
- Chief executive
- Thomas Schinecker
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Roche HoldingROP | $387.48B | 33.1% | 26.7 | +25.84% |
| NovartisNOVN | $305.16B | 34.0% | 32.6 | +14.23% |
| AstraZenecaAZN | $287.12B | 25.8% | 26.6 | +1.25% |
| Novo NordiskNOVO.B | $184.87B | 50.8% | 11.2 | −7.92% |
| SanofiSAN | $116.52B | 22.3% | 25.5 | +17.04% |
| GSKGSK | $102.04B | 30.5% | 18.0 | +0.35% |
Same industry or related industries, similar size. Compare Roche Holding with its competitors · Full profile
